Media

Onxeo to attend Key Investor and Partnering Conferences in the Coming Months

Paris (France), September 13, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, today announced that its management team will attend the following key investor and partnering conferences in the coming months: European Large & Midcap Event October 8-9, 2018 Paris,…read more →

Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook

Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan Preliminary safety and activity results of DRIIV-1 study are expected in Q4 2018 Two combination clinical trials with AsiDNA™ planned for early 2019 New optimized candidate from platON™ proprietary platform ready to enter preclinical stage by end 2018 Cash position of €11m at June 30, 2018 enables an expanded…read more →

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors

AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PARP inhibitors AsiDNA™ combined with olaparib inhibited tumor growth in an in vivo model of ovarian cancer resistant to olaparib AsiDNA™ combined with various PARP inhibitors prevented the occurrence of resistance and reversed…read more →

Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA

Cash for Operations Extended to Q3 2020 Paris (France), June 15, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the initiation of an equity financing line through the issuance of…read more →

Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties

  Transaction reinforces Company’s cash position and proceeds will be fully allocated to the advancement of Onxeo’s pipeline, including its lead product candidate, AsiDNA™   Paris (France), June 7, 2018 – 07h00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, notably against…read more →

Onxeo to Present at BIO International Convention in Boston

Paris (France), May 23, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or resistant forms of cancer, today announced that Judith Greciet, the Company’s Chief Executive Officer, will present at the 25th BIO International Convention. The conference is being…read more →

Onxeo Provides Business Update and Reports First Quarter 2018 Financial Information

Development of lead product candidate, AsiDNA™, for the treatment of advanced solid tumors, progressing according to plan DRIIV phase I clinical trial ongoing Interim results expected in H2 2018 Cash position of €9.2 million at March 31, 2018, sufficient to support Company’s operations until mid-2019, including through multiple key catalysts Paris (France), May 16, 2018 – 06:00 pm CEST –…read more →

Annual General Meeting of May 16, 2018

Approval of all ordinary resolutions Renewal of the terms of office of Mr. Thomas Hofstaetter Notice of a new Extraordinary General Meeting on June 19, 2018  Paris (France), May 16, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or…read more →

Combined General Meeting on May 16, 2018

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced that the Onxeo shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which will be held on Wednesday,…read more →

Publication of 2017 Registration Document

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced the publication of the Company’s 2017 Registration Document. The 2016 Registration Document, filed with the French Market Authorities (Autorité des Marchés Financiers)…read more →

Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor

First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted in three internationally-renowned clinical centers Interim results expected in second half of 2018 Paris (France), April 24, 2018 – 06:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative…read more →

Onxeo to Present Corporate Overview at the H.C. Wainwright Annual Global Life Sciences Conference

Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced that Nicolas Fellmann, CFO of Onxeo, will present and hold one-to-one meetings with investors at the…read more →

Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update

Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, Onxeo’s proprietary development platform, to enter preclinical studies by end of 2018 Cash position of €14.3m at December 31, 2017, to support current operating plan through mid-2019 Paris, March 29, 2018 – 6:00 pm CEST -  Onxeo S.A. (Euronext Paris,…read more →

Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting

Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, today announced the presentation of two preclinical study abstracts highlighting AsiDNA™, the Company’s first-in-class DNA break repair inhibitor candidate, at the upcoming…read more →

Onxeo Provides Financial Update

Paris (France), March 14th, 2018 – 8:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, today announced that it will record an impairment charge of about €38 million in its 2017 consolidated accounts pursuant to value tests…read more →